S. Moein Moghimi, Ph.D.
Director, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, NanoScience Centre, Faculty of Science, University of Copenhagen (Denmark)
|B.S.||University of Manchester, UK (Biochemistry)|
|Ph.D.||Charing Cross and Westminster Medical School, Imperial College, University of Long, UK (Biochemistry)|
Postdoctoral Fellow, Pharmaceutical Sciences, University of Nottingham, UK
Dr. Moghimi earned his Bachelor degree in Biochemistry with Honors from the University of Manchester (UK), and his Doctorate in Biochemistry/Immunobiology from Charing Cross and Westminster Medical School, Imperial College, London. Following postdoctoral training and a University Fellowship at the School of Pharmaceutical Sciences at Nottingham University (UK), he moved to the University of Brighton as a senior lecturer in Biopharmacy and Molecular Therapy. In 2008, he accepted the chair of Nanomedicine at the University of Copenhagen (Denmark), where he currently heads the Nanomedicine Research Group at the School of Pharmacy, Faculty of Health and Medical Sciences. In 2009, he founded the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (CPNN) at the NanoScience Centre of Copenhagen University through a multi-million dollar award by the Strategic Research Council of Denmark, where he acts in the capacity of centre director. Dr. Moghimi is also the honorary professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China) and an elected fellow of the Institute of Nanotechnology in the UK. Since 2009, Dr. Moghimi has secured over US$13 million in competitive research funds in basic and applied nanomedicine research as the principal investigator and is currently a partner in two large-scale competitive European Commission FP-7 programs in translational nanomedicine/drug delivery, addressing Alzheimer’s disease and atherosclerosis with secured budgets of US$ 14.5 million and US$ 11 million, respectively.
Dr. Moghimi serves as the associate editor of Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier) and the Journal of Biomedical Nanotechnology, and sits on the editorial/advisory board of over 15 peer-reviewed international journals, including Advanced Drug Delivery Reviews, Nanomedicine-UK (Future Medicine), and Molecular and Cellular Therapies (BioMed Central). Dr. Moghimi has been a practicing consultant to numerous pharmaceutical, biotechnology, health and food industry companies as well as investment banks, management consultancy firms, and other entrepreneurial enterprises globally for over two decades. He is also a regularly invited assessor and expert evaluator in nanomedicine and pharmaceutical science research centers/research projects for governmental bodies, research councils, and private organizations worldwide (> 50 establishments in 20 countries). As a frequent keynote and guest speaker at many international conferences and organizations, as well as being regular conference chair and organizer, Dr. Moghimi has given over 300 invited speeches and lectures. He has published over 170 peer-reviewed articles in prestigious international journals and book chapters, and is the inventor of many patents.
Dr. Moghimi’s research activities are focused on pharmaceutical nanoscience, nanotechnology in iMedicine, nanotoxicology and fundamental/translational nanomedicine in relation to cancer, neurodegenerative diseases, cardiovascular diseases, and immunological disorders. He has pioneered research in the design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (e.g., splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles, cancer nanomedicine, cerebral endothelial-specific nanoparticle-fiber networks) as well as the molecular basis of nanomaterial immune toxicity, polymer cytotoxicity, and preventive measures.
brain targeting, cancer, complement system, nanomedicine, nanotoxicology
Andersen AJ, Robinson JT, Dai H, Hunter AC, Andresen TL, Moghimi SM. Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano. 2013 Feb 26;7(2):1108-19. PMID: 23301860
Benjaminsen RV, Mattebjerg MA, Henriksen JR, Moghimi SM, Andresen TL. The possible ‘proton-sponge’ effect of polyethylenimine does not include change in lysosomal pH. Mol Ther. (Am Soc Gene Cell Ther.) 2013 Jan;21(1):147-57. PMID: 23032976
Hamad I, Hunter AC, Moghimi SM. Complement activation by pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins A-I and B-100. J Control Rel. 2013 Sep 10;170(2):167-74. PMID: 23747733
Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P, Christensen C. Underlying oxidative phosphorylation dysfunction makes malignant melanoma cells addicted to glycolysis driven by the V600E BRAF oncogene. Oncotarget. 2013 Apr;4(4):584-99. PMID: 23603840
Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Rahimi Jamnani F, Moghimi SM. Genetically engineered cytotoxic T cells bearing nanoconstructed chimeric receptors harbouring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett. 2013 Jul 1;334(2):237-44. PMID: 22902507
Brambilla D, Verpillot R, Le Droumaguet B, Nicolas J, Taverna M, Kona J, Lettiero B, Hashemi SH, De Kimpe L, Canovi M, Gobbi M, Nicolas V, Scheper W, Moghimi SM, Tvaroska I, Couvreur P, Andrieux K. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: Towards engineering of functional nanomedicines for Alzheimer’s disease. ACS Nano. 2012 Jul 24;6(7):5897-908. PMID: 22686577
Moghimi SM, Wibroe PP, Helvig S, Farhangrazi ZS, Hunter AC. Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward. Adv Drug Deliv Rev. 2012 Oct;64(13):1385-93. PMID: 22634159
Moghimi S M, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: An integrated analysis and perspective. Anun Rev Pharmacol Toxicol. 2012;52:481-503. PMID: 22035254
Moghimi SM, Peer D, Langer R. Re-shaping the future of nanopharmaceuticals: ad iduicium. ACS Nano. 2011 Nov 22;5(11):8454-8. PMID: 21992178
Sadeqzadeh E, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Parhamifar L, Moghimi SM. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J Control Rel. 2011 Nov 30;156(1):85-91. PMID: 21704663
Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at nanosphere-serum interface: Implications for stealth nanoparticle engineering. ACS Nano. 2010 Nov 23;4(11):6629-38. PMID: 21028845
Moghimi SM, Hunter AC. Complement monitoring of carbon nanotubes. Nature Nanotechnol. 2010 Jan;5(6): 382. PMID: 20523330